In the last trading session, 1.6 million Neogenomics Inc (NASDAQ:NEO) shares changed hands as the company’s beta touched 1.53. With the company’s per share price at $9.97 changed hands at -$0.3 or -2.92% during last session, the market valuation stood at $1.28B. NEO’s last price was a discount, traded about -91.68% off its 52-week high of $19.11. The share price had its 52-week low at $8.05, which suggests the last value was 19.26% up since then. When we look at Neogenomics Inc’s average trading volume, we note the 10-day average is 1.51 million shares, with the 3-month average coming to 1.46 million.
Analysts gave the Neogenomics Inc (NEO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NEO as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Neogenomics Inc’s EPS for the current quarter is expected to be -0.01.
Neogenomics Inc (NASDAQ:NEO) trade information
Instantly NEO was in red as seen at the end of in last trading. With action 4.07%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -39.50%, with the 5-day performance at 4.07% in the green. However, in the 30-day time frame, Neogenomics Inc (NASDAQ:NEO) is 5.17% up. Looking at the short shares, we see there were 4.98 million shares sold at short interest cover period of 2.79 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need an upside of 44.61% from its current market value. According to analyst projections, NEO’s forecast low is 18 with 18 as the target high. To hit the forecast high, the stock’s price needs a -80.54% plunge from its current level, while the stock would need to soar -80.54% for it to hit the projected low.
Neogenomics Inc (NEO) estimates and forecasts
Year-over-year growth is forecast to reach 11.76% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 170.9M. 13 analysts are of the opinion that Neogenomics Inc’s revenue for the current quarter will be 182.94M. The company’s revenue for the corresponding quarters a year ago was 156.24M and 164.5M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 9.38%. The estimates for the next quarter sales put growth at 11.21%.
The 2025 estimates are for Neogenomics Inc earnings to increase by 61.77%, but the outlook for the next 5-year period is at 75.33% per year.
NEO Dividends
Neogenomics Inc is expected to release its next quarterly earnings report on 2025-Feb-17.
Neogenomics Inc (NASDAQ:NEO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.07% of Neogenomics Inc shares while 102.19% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.29%. There are 102.19% institutions holding the Neogenomics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 15.5612% of the shares, roughly 19.67 million NEO shares worth $272.82 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1716% or 14.12 million shares worth $195.87 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 7.94 shares estimated at $79.12 million under it, the former controlled 6.17% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.07% of the shares, roughly 3.95 shares worth around $39.39 million.
